ATE525078T1 - Kyberdrug als autovakzine mit immunregulierenden wirkungen - Google Patents

Kyberdrug als autovakzine mit immunregulierenden wirkungen

Info

Publication number
ATE525078T1
ATE525078T1 AT01986266T AT01986266T ATE525078T1 AT E525078 T1 ATE525078 T1 AT E525078T1 AT 01986266 T AT01986266 T AT 01986266T AT 01986266 T AT01986266 T AT 01986266T AT E525078 T1 ATE525078 T1 AT E525078T1
Authority
AT
Austria
Prior art keywords
kyberdrug
autovaccine
immune
regulatory effects
activities
Prior art date
Application number
AT01986266T
Other languages
English (en)
Inventor
Henrich H Paradies
Volker Rusch
Kurt Zimmermann
Original Assignee
Symbio Herborn Group Gmbh U Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symbio Herborn Group Gmbh U Co filed Critical Symbio Herborn Group Gmbh U Co
Application granted granted Critical
Publication of ATE525078T1 publication Critical patent/ATE525078T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/315—Zinc compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/185—Escherichia
    • C12R2001/19—Escherichia coli

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT01986266T 2000-10-06 2001-10-05 Kyberdrug als autovakzine mit immunregulierenden wirkungen ATE525078T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23865600P 2000-10-06 2000-10-06
US26349401P 2001-01-23 2001-01-23
PCT/IB2001/002284 WO2002028424A2 (en) 2000-10-06 2001-10-05 Kyberdrug as autovaccines with immune-regulating effects

Publications (1)

Publication Number Publication Date
ATE525078T1 true ATE525078T1 (de) 2011-10-15

Family

ID=26931842

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01986266T ATE525078T1 (de) 2000-10-06 2001-10-05 Kyberdrug als autovakzine mit immunregulierenden wirkungen

Country Status (7)

Country Link
US (1) US20020155997A1 (de)
EP (1) EP1341546B1 (de)
JP (1) JP2004510746A (de)
AT (1) ATE525078T1 (de)
AU (1) AU2002223970A1 (de)
CA (1) CA2436107C (de)
WO (1) WO2002028424A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2260053C2 (ru) * 2002-06-26 2005-09-10 Апарин Петр Геннадьевич Способ выделения биологически активной фракции (баф), содержащей s-липополисахариды (s-лпс) из грамотрицательных бактерий, баф для лечения и профилактики заболеваний, вызываемых грамотрицательными бактериями, производящими эндотоксичные s-лпс, фармацевтическая композиция, способы индукции протективного иммунитета и улучшения состояния пациента при состояниях, требующих повышения иммунного статуса
HUE036180T2 (hu) 2006-09-26 2018-06-28 Infectious Disease Res Inst Szintetikus adjuvánst tartalmazó vakcina készítmény
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US8277446B2 (en) * 2009-04-24 2012-10-02 Tyco Healthcare Group Lp Electrosurgical tissue sealer and cutter
HUE031051T2 (en) 2009-06-05 2017-06-28 Infectious Disease Res Inst Synthetic glycopyranosyl lipid adjuvant and vaccine compositions containing it
US9200251B1 (en) 2011-03-31 2015-12-01 David Gordon Bermudes Bacterial methionine analogue and methionine synthesis inhibitor anticancer, antiinfective and coronary heart disease protective microcins and methods of treatment therewith
EP3632463A1 (de) 2011-04-08 2020-04-08 Immune Design Corp. Immunogene zusammensetzungen und verfahren zur verwendung der zusammensetzungen zur induzierung humoraler und zellulärer immunreaktionen
SI2850431T1 (en) 2012-05-16 2018-08-31 Immune Design Corp. Vaccines for hsv-2
EP2986303B1 (de) 2013-04-18 2020-02-26 Immune Design Corp. Gla-monotherapie zur verwendung in der krebsbehandlung
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
CN116355112B (zh) * 2023-03-31 2025-07-08 吉林农业科技学院 小分子量平贝母多糖、平贝母多糖纳米硒复合物、其制备方法及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029762A (en) * 1971-11-17 1977-06-14 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Lipid A-preparation
US4844894A (en) * 1984-07-12 1989-07-04 Ribi Immunochem Research Inc. Method of inhibiting the onset of septicemia and endotoxemia
US5888519A (en) * 1988-06-02 1999-03-30 The United States Of America As Represented By The Secretary Of The Army Encapsulated high-concentration lipid a compositions as immunogenic agents to produce human antibodies to prevent or treat gram-negative bacterial infections
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP0689454B2 (de) * 1993-03-23 2005-02-23 SMITHKLINE BEECHAM BIOLOGICALS s.a. 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
FR2733151B1 (fr) * 1995-04-20 1997-05-23 Seppic Sa Composition therapeutique comprenant un antigene ou un generateur in vivo d'un compose comprenant une sequence d'acides amines
US5997881A (en) * 1995-11-22 1999-12-07 University Of Maryland, Baltimore Method of making non-pyrogenic lipopolysaccharide or A
US6887483B2 (en) * 1995-12-01 2005-05-03 University Of Iowa Research Foundation Non-toxic mutants of pathogenic gram-negative bacteria
WO1997025061A1 (en) * 1996-01-09 1997-07-17 Bristol-Myers Squibb Company De-myristolated lipopolysaccharide of gram-negative bacteria
US6368604B1 (en) * 1997-09-26 2002-04-09 University Of Maryland Biotechnology Institute Non-pyrogenic derivatives of lipid A
US6482807B1 (en) * 1998-11-03 2002-11-19 De Staat Der Nederlanden, Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur LPS with reduced toxicity from genetically modified gram negative bacteria

Also Published As

Publication number Publication date
JP2004510746A (ja) 2004-04-08
CA2436107A1 (en) 2002-04-11
WO2002028424A9 (en) 2003-09-12
CA2436107C (en) 2012-05-22
WO2002028424A3 (en) 2002-11-07
US20020155997A1 (en) 2002-10-24
AU2002223970A1 (en) 2002-04-15
EP1341546B1 (de) 2011-09-21
WO2002028424A2 (en) 2002-04-11
EP1341546A2 (de) 2003-09-10

Similar Documents

Publication Publication Date Title
NO20022998D0 (no) Farmasöytiske preparater som tilveiebringer foröket konsentrasjon av medikament
DK1365808T3 (da) Sammensætninger til antitumorbehandling indeholdende ecteinascidin 743
DE60138948D1 (de) Medizinische aerosolformulierung von antidiabetika
ATE312080T1 (de) 2-chinolonen enthaltende arzneimittel
AP9801169A0 (en) N-hydroxy-B-sulfonyl propionamide derivatives.
DE3686483D1 (de) Arzneimittel.
ES2183841T3 (es) Formas de dosificacion para administrar un farmasco en una formulacion lquidid.
DE60108154D1 (de) Pharmazeutische Zubereitungen enthaltend Clavulansäure
ATE324907T1 (de) Verbindung und arzneizusammensetzung zur verabreichung von wirkstoffen
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
ATE525078T1 (de) Kyberdrug als autovakzine mit immunregulierenden wirkungen
CO4290432A1 (es) Nuevos derivados de pirazinacarboxamida, su preparacion y su utilizacion en medicamentos.
DK1283038T3 (da) Dögnrytmenormaliserende sammensætninger
NZ505919A (en) Nasal solutions
MY124146A (en) Novel 2-(iminomethyl) amino-phenyl derivatives, preparation, application as medicines and pharmaceutical compositions containing same
DE60211139D1 (de) Feste arzneizusammensetzung enthaltend 4'-cyano-trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy-2-methylpropiono- m toluidide und pvp
IT1263840B (it) Formulazioni orali di ubidecarenone in forma di capsule
AR029509A1 (es) Una composicion farmaceutica en base a un compuesto de platino (iv) y el uso de dicho compuesto para preparar medicamentos antitumorales
ATE107853T1 (de) Orales, melatonin enthaltendes arzneimittel.
HRP20080117A2 (en) Pharmaceutical composition for modified release insulin sensitiser
HUP0001104A2 (hu) Ibuprofent és domperidont tartalmazó készítmények migrén kezelésére
DE69803054D1 (de) Zusammensetzung auf der basis von pflanzenextrakten und ätherischen ölen, verwendbar in therapeutika, kosmetika und diätnahrung
FR2821080B1 (fr) Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques
RU94032792A (ru) Применение 5нтiа - антагонистов для прекращения использования табака
DE60112578D1 (de) Pharmazeutische diclofenac-verbindung basierend auf vitamin e, papain und hyaluronidase